NCT01743027View on ClinicalTrials.gov

Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis

PHASE3CompletedINTERVENTIONAL
Enrollment

902

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Allergic Conjunctivitis
Interventions
DRUG

AL-4943A ophthalmic solution

DRUG

Olopatadine hydrochloride ophthalmic solution, 0.2%

DRUG

Olopatadine hydrochloride ophthalmic solution, 0.1%

DRUG

AL-4943A ophthalmic solution vehicle

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
lead

Alcon Research

INDUSTRY